NEW YORK, Nov. 20 /PRNewswire/ -- Clinical data from a prospective registry presented this week at the 35th Annual Veith Symposium shows DVT treatment with the Trellis(R) Peripheral Infusion System from Bacchus Vascular, Inc. (Santa Clara, CA) successfully breaks up the blood clot in most patients in about 20 minutes.
This technique, called isolated pharmacomechanical thrombolysis, restores blood flow more quickly and safely than current catheter-directed thrombolysis (CDT) techniques. It provides an important adjunct to anti-coagulation alone, the current standard of care, which does not break up the existing clot but simply prevents further clot from forming.
Alan M. Dietzek, MD, Chief of Vascular and Endovascular Surgery at Danbury Hospital, Danbury, Connecticut reported the latest outcomes from the manufacturer's registry of clinical results with the Trellis System at over 360 hospitals in the U.S. and internationally.
In a total of 1,409 limbs treated in 1,304 patients, Grades II and III lysis with restoration of patency in patients with all clot chronicities were achieved in 95% of cases. The vast majority of cases (> 83%) were completed in less than two hours in the single-setting of an interventional suite; and the usage of the Trellis System was typically around 20 minutes. No follow-up monitoring in a costly critical care or intensive care unit was typically needed with the Trellis System, in contrast to this requirement of CDT procedures.
There were no reported bleeding complications related to the Trellis device in acute follow up and the dosage of thrombolytic drugs such as t-PA was reduced by 30% with use of the Trellis device compared to CDT.
"Profound changes in the treatment paradigm for DVT are now underway, as evidenced by the U.S. Surgeon General's recent DVT Call to Action," said Dr. Dietzek. "New clinical guidelines in 2008 from the American College of Chest Physicians and the National Quality Forum support the early removal of blood clots with devices like the Trellis System and clinical data on the use of the device underscore the importance of its growing role."
"The Trellis System multicenter clinical data registry has grown into the world's largest reported prospective endovascular series of DVT patients," stated Scott Cramer, President and CEO of Bacchus Vascular. "We are pleased to see how the increasing clinical utilization of our products is propelling the Company's success."
For more information on the changing treatment paradigm for DVT, visit www.DVT-Revolution.org.
About Bacchus Vascular
Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products. For more information, visit www.bacchusvascular.com.
Now in its fourth decade, VEITHsymposium(TM) provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features over 400 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Press registration details can be found at www.VEITHpress.org. VEITHsymposium is sponsored by Cleveland Clinic (Cleveland, OH).
CONTACT: Dennis Rosenberg, VP Marketing of Bacchus Vascular, Inc.,
+1-408-980-8300, ext. 260, email@example.com
Web site: http://www.bacchusvascular.com/